Abstract: The present invention relates to compositions and fusion proteins containing at least two Mycobacterium sp.) antigens, and polynucleotides encoding such compositions and fusion proteins. The invention also relates to methods for their use in the treatment, prevention and/or diagnosis of tuberculosis infections.
Type:
Grant
Filed:
July 6, 2021
Date of Patent:
February 13, 2024
Assignee:
ACCESS TO ADVANCED HEALTH INSTITUTE
Inventors:
Steven G. Reed, Rhea N. Coler, Gregory C. Ireton, Sylvie Bertholet
Abstract: Compositions and methods for preventing, treating and detecting leprosy are disclosed. The compositions generally comprise polypeptides comprising one or more Mycobacterium leprae antigens as well as polynucleotides encoding such polypeptides.
Abstract: The invention provides for thermostable lyophilized formulations, including vaccines and pharmaceutical compositions for inducing or enhancing an immune response, and methods of use thereof. The lyophilized formulations generally comprise an antigen and/or an adjuvant, a metabolizable oil, and a cake-forming excipient.
Type:
Grant
Filed:
December 29, 2014
Date of Patent:
October 31, 2023
Assignee:
ACCESS TO ADVANCED HEALTH INSTITUTE
Inventors:
Christopher B. Fox, Thomas Vedvick, Lucien Barnes V., Ryan M. Kramer, Steven G. Reed
Abstract: A method of using the transverse relaxation rate (R2) of solvent NMR signal to noninvasively assess alum-containing products such as vaccines. This technique can be used for quality control in vaccine manufacturing (e.g., fill-finish step) to determine the evenness of alum filling level as well as extent of alum particle sedimentation in filled and sealed products.
Type:
Grant
Filed:
October 4, 2019
Date of Patent:
February 21, 2023
Assignees:
UNIVERSITY OF MARYLAND, BALTIMORE, ACCESS TO ADVANCED HEALTH INSTITUTE
Inventors:
Yihua (Bruce) Yu, Marc Taraban, Christopher Fox
Abstract: Formulations and methods, including vaccines and pharmaceutical compositions for inducing or enhancing an immune response are disclosed. The formulations generally comprise a TLR4 agonist and a metabolizable oil at a concentration of about 0.01%-1% v/v, wherein the hydrophobic:lipophilic balance (HLB) of the emulsion is greater than about 9.
Type:
Grant
Filed:
February 7, 2013
Date of Patent:
November 29, 2022
Assignee:
ACCESS TO ADVANCED HEALTH INSTITUTE
Inventors:
Christopher Fox, Steven G. Reed, Susan Baldwin, Thomas Vedvick
Abstract: Compositions and methods, including vaccines and pharmaceutical compositions for inducing or enhancing an immune response are disclosed based on the discovery of useful immunological adjuvant properties in a synthetic, glucopyranosyl lipid adjuvant (GLA) that is provided in substantially homogeneous form. Chemically defined, synthetic GLA offers a consistent vaccine component from lot to lot without the fluctuations in contaminants or activity that compromise natural-product adjuvants. Also provided are vaccines and pharmaceutical compositions that include GLA and one or more of an antigen, a Toll-like receptor (TLR) agonist, a co-adjuvant and a carrier such as a pharmaceutical carrier.
Abstract: The present disclosure relates to methods and compositions for treating a active tuberculosis infection and methods and compositions for improving the efficacy of chemotherapy regimens against active tuberculosis infection. The present disclosure relates to methods of treating an active M. tuberculosis infection or an active infection resulting from reactivation of a latent infection in a mammal and to methods of improving the efficacy of chemotherapy regimens against active M. tuberculosis infection.
Abstract: Stable aqueous formulations of adjuvant comprising a TLR7/8 agonist or a TLR4 agonist with a helper lipid that are adsorbed to alum are provided. Compositions and methods of using the formulations for stimulating an immune response are also provided.